Abstract
Public health focused on drug use is considered a balancing act between preventing illicit use of drugs of abuse and ensuring access to drugs/medicines with abuse potential for a medical condition. Whereas clinically relevant drug interactions for medicines are widely recognized and are included in most pharmacovigilance systems, drug interactions with drugs of abuse are mainly underexplored, and their assessment is not part of clinical routine. An excellent example of this paradigm is 3,4-methylenedioxymethamphetamine (MDMA, ecstasy, or molly), one of the most popular recreative psychostimulants, which is being currently evaluated for the treatment of post-traumatic stress disorder. Considering both aspects of MDMA, as a consolidated recreational drug of abuse and a potential medicine, it is crucial to understand which inter-and intraindividual factors, modulation factors, and potential interactions could lead to risk of intoxication in recreational drug users as well as in patients with possible future MDMA-assisted therapy.
| Original language | English |
|---|---|
| Title of host publication | Handbook of Substance Misuse and Addictions |
| Subtitle of host publication | From Biology to Public Health |
| Publisher | Springer International Publishing AG |
| Pages | 2243-2268 |
| Number of pages | 26 |
| ISBN (Electronic) | 9783030923921 |
| ISBN (Print) | 9783030923914 |
| DOIs | |
| Publication status | Published - 1 Jan 2022 |
Keywords
- 3, 4-methylenedioxymethamphetamine
- Acute toxicity
- Cytochrome P450 2D6 (CYP2D6)
- Drug interaction
- Drug of abuse
- Drug/Medicine
- Genetic polymorphisms
- MDMA
- Pharmacodynamics (PD)
- Pharmacokinetics (PK)
- Polydrug use
- Post-traumatic stress disorder (PTSD)
- Race/Ethnicity
- Sex/Gender
